lilly tirzepatide approval https://investor.lilly.com/news-releases/news-release-details/zepbound- tirzepatide-most-prescribed-weight-management “Eli and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound Diabetes drug resolves sleep apnea

(Mine is pictured to the left!) Super Lipo B $50/week or $150 for the month Semaglutide Tirzepatide Super MIC $30/week SUPER LIPO B INJECTION Telemedicine visits are required with our Medical Director monthly

Important Safety Information Because isotretinoin can cause serious side effects, including birth defects, regular medical supervision is mandatory

Semaglutide 24 mg once a week in adults with overweight or obesity, and type 2 diabetes (step 2): a randomized, double-blind, double-dummy, placebo-controlled, phase 3 trial

The precautionary principle would suggest we do our best to prevent aspiration events in these patients unless we have clear, high-quality evidence that patients taking GLP-1 RAs are not at increased risk of aspiration

Are 1-Month Weight Loss Results the Same for Everyone

Providers should carefully screen candidates, counsel them on risks, and monitor for adverse events